CDMO– tag –
-
Minaris Expands GMP Cell Banking Capabilities in Philadelphia, Enhancing Cell & Gene Therapy CDMO Services
Contract Pharma USA Overview Minaris has significantly enhanced its GMP cell banking suite at its Philadelphia facility, expanding its cell and gene therapy (CGT) CDMO services. This upgrade enables comprehensive support for clinical and... -
Tacit Knowledge Loss in Cell & Gene Therapy Tech Transfer Poses Critical Threat to Manufacturing Yield and Quality
Drug Discovery and Development USA Overview The transfer of cell and gene therapy manufacturing processes is severely hampered by the loss of tacit knowledge, impacting product yield and quality. Manual steps in CAR-T cell production, su... -
Pharmaceutical CDMO Market Report: Capital Investments and Advanced Therapies Drive Growth
Global Market Insights Global Overview This article provides an overview of the Pharmaceutical CDMO Market research report published by Global Market Insights. The report highlights significant capital investments and major expansions wi... -
Bispecific Antibody CDMO Market to Surge to $603.13 Billion by 2035, Driven by Diverse Asymmetric Formats
PharmaSource UK Overview This article outlines a market research report from PharmaSource on the bispecific antibody CDMO market, projected to skyrocket from $25.94 billion in 2026 to approximately $603.13 billion by 2035. A key market t... -
Biologics CDMO Market Competitive Landscape Report: Lonza, Samsung Biologics, and WuXi Biologics Drive Growth
National Law Review USA Overview This article summarizes a report on the competitive landscape and growth drivers of the biologics CDMO market. Key players include Lonza Group Ltd, Samsung Biologics Co Ltd, WuXi Biologics Cayman Inc, The... -
FUJIFILM Completes £400M UK Teesside CDMO Expansion, Accelerating Bioprocess Innovation and Cell Product Diversification
Fujifilm Japan Overview FUJIFILM announced significant life sciences advancements at BIO 2026, notably completing a £400 million investment in its UK Teesside manufacturing facility, making it the largest single-use CDMO site in the coun... -
Ernexa Therapeutics Accelerates iPSC-Derived MSC Manufacturing with Japan JEAP Selection, Highlighting Japan’s CDMO Ecosystem as Key
Clinical Leader USA Overview Ernexa Therapeutics has been selected for Japan's Entry Acceleration Program (JEAP), gaining a critical opportunity to advance its induced pluripotent stem cell (iPSC)-derived mesenchymal stem cell (iMSC) pla... -
WuXi Biologics Suzhou BioSafety Testing Center Secures Fourth EMA GMP Certification, Enabling 19 Commercial Products for European Market
WuXi Biologics China Overview WuXi Biologics' Suzhou BioSafety Testing Center has successfully renewed its European Medicines Agency (EMA) GMP certification for the fourth time. This accreditation enables the center to support quality te... -
Advancing Cell Therapy Production: CCRM, OmniaBio, and Avectas Pioneer Automated Hub-and-Spoke Model for CAR-T, iPSC, and Lentiviral Vectors
PR Newswire (CCRM) Canada, アイルランド Overview CCRM and its CDMO subsidiary, OmniaBio, have partnered with Avectas Limited to evaluate an automated, integrated, and scalable cell therapy manufacturing platform. This strategic alliance ... -
CDMO Signal Ranks Lentiviral Vector (LVV) CDMOs: GMP Standards and Robust Assays Key for Selection
CDMO Signal USA Overview CDMO Signal published its ranking of Lentiviral Vector (LVV) CDMOs based on Signal Score. LVVs are critical in ex vivo gene therapies for engineering CAR-T cells and modifying hematopoietic stem cells, necessitat...
